FIELD: pharmaceutics.
SUBSTANCE: invention relates to a co-crystal of a compound (I) and a molecule of a co-component
where the molecule of the co-component is phosphoric acid, while the co-crystal is a hydrate and the molar ratio of compound (I):phosphoric acid:H2O in the specified co-crystal is 1:2:1/2, to the methods for obtaining the co-crystal and pharmaceutical compositions containing the specified co-crystal.
EFFECT: new co-crystal is obtained that demonstrates increased plasma concentrations, and that can be used in the production of a drug for use in the treatment of cancer associated with overexpression of TTK.
17 cl, 6 tbl, 5 ex, 7 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| SALTS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASE | 2013 |
|
RU2711077C2 |
| SULFONAMIDE COMPOUNDS AND THEIR USE | 2018 |
|
RU2781383C2 |
| SODIUM BENZOATE COCRYSTALS AND THEIR USE | 2017 |
|
RU2771810C2 |
| LITHIUM BENZOATE CO-CRYSTALS AND THEIR APPLICATIONS | 2017 |
|
RU2765625C2 |
| PHARMACEUTICAL COMPOUND | 2018 |
|
RU2786994C2 |
| CRYSTALLINE FUMARATE SALT OF (S)-[3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)PHENYL][3-HYDROXY-3-(PIPERIDINE-2-YL)AZETIDINE-1-YL]METHANONE | 2016 |
|
RU2762181C2 |
| CO-CRYSTALLINE FORMS OF TRAMADOL AND NSAID | 2009 |
|
RU2599717C2 |
| TRIAZINE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST VIRUS REPLICATION, AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2022 |
|
RU2806042C1 |
| SOLID FORMS OF PLADIENOLIDE PYRIDINE COMPOUNDS AND METHODS FOR USE THEREOF | 2016 |
|
RU2743349C2 |
| CO-CRYSTALLINE FORM OF BICALUTAMIDE | 2012 |
|
RU2510392C1 |
